Surface Oncology Inc. (NASDAQ:SURF) saw an upside of 0.51% to close Tuesday at $7.87 after adding $0.04 on the day. The 5-day average trading volume is 833,940 shares of the company’s common stock. It has gained $8.32 in the past week. An average of 1,770,480 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,063,234.
SURF’s 1-month performance is 29.87% or $1.76 on its low of $5.83 reached on 09/14/21. The company’s shares have touched a 52-week low of $4.95 and high of $14.40, with the stock’s rally to the 52-week high happening on 01/21/21. YTD, SURF has lost -14.83% or -$1.37. However, the current price is down -45.35%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Jun 11, 124 days have gone by since the last insider trading activity for Surface Oncology Inc. (SURF). Goater Jeff (Director) most recently sold 15,273 shares at $7.61 per share on Jun 11. This transaction cost the insider $116,226. Director, Goater Jeff, sold 234,727 shares at a price of $7.66 on Jun 10. Then, on Feb 16, Chief Medical Officer ROSS ROBERT W. sold 1,000 shares at a price of $11.35 per share. This transaction amounted to $11,350.
The company’s PE ratio for the last five years has touched a high of 25.25 and a low of 4.932. SURF stock has a beta of 1.65. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.93 while the price-to-book (PB) in the most recent quarter is 2.32.
Surface Oncology Inc.’s quick ratio for the period ended June 29 was 9.10, with the current ratio over the same period at 9.10 meaning that SURF stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.07, while the total debt to equity was 0.10The trailing 12-month EBITDA margin is 51.68% while for the period ending June 29; Surface Oncology Inc.’s operating margin was 20.50%. The firm’s gross profit as reported stood at $64.58 million against revenue of $126.16 million.
For the quarterly period ending June 29 this year, Surface Oncology Inc.’s cash and short-term investments amounted to $80.95 million against total debt of $47.5 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 100.0% to $0.52 million, while revenue of $1.63 million was -213.46% off the previous quarter. Analysts expected SURF to announce -$0.35 per share in earnings in its latest quarter, but it posted -$0.44, representing a -25.70% surprise. EBITDA for the quarter stood at more than -$17.98 million. SURF stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 57.43 million, with total debt at $47.5 million. Shareholders hold equity totaling $45.45 million
Let’s look briefly at Surface Oncology Inc. (SURF) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 65.00% to suggest the stock is trending Neutral, with historical volatility in this time period at 30.16%.
The stock’s 5-day moving average is $7.72, reflecting a +2.88% or $0.22 change from its current price. SURF is currently trading +32.49% above its 20-day SMA, -9.02% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +29.02% and -18.28% respectively.
Stochastic %K and %D was 66.19% and 62.45% and the average true range (ATR) pointed at 0.46. The RSI (14) points at 63.81%, while the 14-day stochastic is at 63.71% with the period’s ATR at 0.46. The stock’s 9-day MACD Oscillator is pointing at 0.10 and 0.17 on the 14-day charts.
In the most recent analyst report for Surface Oncology Inc. (NASDAQ: SURF), BTIG Research launched coverage with a Buy rating. Analysts offering their rating for SURF stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate SURF as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 5 have offered a “buy” rating.
What is SURF’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $14.00 and a high of $18.00, with their median price target at $17.00. Looking at these predictions, the average price target given by analysts is for Surface Oncology Inc. (SURF) stock is $16.40.